MedTrace Logo

Cerebrotendinous Xanthomatosis (CTX) Prevalence Study

NCT02638220 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 442

Last updated 2024-09-19

Study results available
· View outcomes & findings →

Summary

Iiopathic bilateral cataracts occur in many children with Cerebrotendinous Xanthomatosis (CTX) so the opportunity to use contact with health care providers in connection with pediatric cataract evaluation and treatment is a promising avenue for disease detection and prevention.

Conditions

  • Cerebrotendinous Xanthomatosis (CTX)

Sponsors & Collaborators

  • Travere Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Executive Director, Clinical Development Nephrology · Travere Therapeutics, Inc.

Eligibility

Min Age
2 Years
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2021-02-19
Completion
2021-02-19

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02638220 on ClinicalTrials.gov